Aclaris Therapeutics
ACRS
57 hedge funds and large institutions have $65.7M invested in Aclaris Therapeutics in 2020 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 12 increasing their positions, 22 reducing their positions, and 10 closing their positions.
6,800% more call options, than puts
Call options by funds: $69K | Put options by funds: $1K
42% more capital invested
Capital invested by funds: $46.1M → $65.7M (+$19.6M)
8% less funds holding
Funds holding: 62 → 57 (-5)
8.16% less ownership
Funds ownership: 67.97% → 59.82% (-8.2%)
45% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 22
50% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCMI
Foresite Capital Management III
Larkspur,
California
|
+$1.53M |
| 2 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$967K |
| 3 |
JGC
J. Goldman & Co
New York
|
+$887K |
| 4 |
Renaissance Technologies
New York
|
+$344K |
| 5 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
+$325K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MP
MFN Partners
Boston,
Massachusetts
|
-$5.41M |
| 2 |
SB
Samsara BioCapital
Palo Alto,
California
|
-$1.02M |
| 3 |
ECM
Endurant Capital Management
San Mateo,
California
|
-$662K |
| 4 |
TI
Telemetry Investments
New York
|
-$462K |
| 5 |
Jane Street
New York
|
-$386K |
ACRS Hedge Fund Activity: Q3 2020 in Review
57 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Aclaris Therapeutics (ACRS) for Q3 2020, worth a combined $65.7M — up 42% from $46.1M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of ACRS and 5 opened new positions — a net loss of 5 holders — while 22 trimmed existing stakes and 12 added.
The largest buyer was Foresite Capital Management III, opening a new position worth an estimated $1.53M. The largest seller was MFN Partners, exiting entirely with an estimated $5.41M sold.
- 57 institutional investors held Aclaris Therapeutics (ACRS) as of Q3 2020, down from 62 in Q2 2020.
- Funds reported $65.7M of Aclaris Therapeutics stock for Q3 2020, up 42% quarter-over-quarter.
- 5 funds opened new Aclaris Therapeutics positions in Q3 2020 and 10 closed out, a net change of -5 holders.
- The largest Aclaris Therapeutics buyer in Q3 2020 was Foresite Capital Management III, an estimated $1.53M added.
- The largest Aclaris Therapeutics seller in Q3 2020 was MFN Partners, an estimated $5.41M sold.
Based on aggregated 13F filings for Q3 2020.